Table 2. The baseline biochemical parameters of the patients.
| Variable | Placebo group, (n=49) | NAM group, (n=49) | P* |
|---|---|---|---|
| Phosphorus (mmol/L) | 2.48±0.50 | 2.49±0.50 | 0.936 |
| Total calcium (mmol/L) | 2.19±0.21 | 2.18±0.26 | 0.088 |
| Intact PTH (pmol/L) | 239.45±70.38 | 240.27±71.63 | 0.954 |
| 25-OH vitamin D (ng/mL) | 26.14±4.87 | 27.19±4.48 | 0.267 |
| Albumin (g/L) | 42.04±4.17 | 42.91±3.95 | 0.293 |
| AST (IU/L) | 9 [7, 12.5] | 10 [8, 14.5] | 0.185 |
| ALT (IU/L) | 7 [6, 12] | 8 [6, 11] | 0.915 |
| C-reactive protein (mg/L) | 5.5±1.8 | 5.6 ±1.6 | 0.682 |
| Hemoglobin (g/dL) | 108.02±14.42 | 108.98±11.10 | 0.713 |
| Platelet count (103/mm3) | 201±50 | 198±63 | 0.842 |
| Triglycerides (mmol/L) | 1.92±0.73 | 1.94±0.89 | 0.889 |
| HDL cholesterol (mmol/L) | 1.03±0.26 | 1.02± 0.33 | 0.903 |
| LDL cholesterol (mmol/L) | 2.71±0.82 | 2.72±0.80 | 0.961 |
Data are reported as the mean ± SD or the median [interquartile range] (for variables with a non-Gaussian distribution). *, the placebo versus the NAM group at the baseline. NAM, nicotinamide; AST, aspartate aminotransferase; ALT, alanine aminotransferase.